Department of Psychiatry, Maastricht University Medical Center, Maastricht, The Netherlands.
Mov Disord. 2011 Feb 15;26(3):407-15. doi: 10.1002/mds.23184. Epub 2011 Mar 7.
Anxiety is a prevalent and disabling condition in Parkinson's disease (PD). The lack of anxiety rating scales validated for this population hampers research into anxiety in PD. The aim of this study is to assess the clinimetric properties of the Hamilton anxiety rating scale (HARS), the Beck anxiety inventory (BAI), and the hospital anxiety and depression scale (HADS) in PD patients.
Three hundred forty-two PD patients underwent a standardized assessment including a structured interview for diagnostic and statistical manual diagnoses of anxiety disorders and completion of the HARS, BAI, and HADS. Inter-rater reliability of the HARS was assessed in 60 patients; test-retest reliability of the BAI and HADS in 213 and 217 patients, respectively.
Thirty-four percent of patients suffered from an anxiety disorder, whereas an additional 11.4% had clinically significant anxiety symptoms in the absence of a diagnosis of anxiety disorder. Acceptability, score distribution, and known groups validity over different levels of anxiety were adequate. Inter-rater reliability for the HARS and test-retest reliability for the BAI and HADS were good. The HARS, but not the BAI and HADS, had a satisfactory inter-item correlation, convergent validity and factorial structure. For all scales, the positive predictive value was poor, and the negative predictive value was moderate.
Given the adequate known groups validity of all three rating scales, each of these scales is likely to be useful in clinical practice or research for evaluation of symptom severity. Limitations in the construct validity of the anxiety scales in this study raise questions regarding suitability for their use in PD.
焦虑是帕金森病(PD)中一种普遍且使人丧失能力的疾病。缺乏针对该人群的经过验证的焦虑评定量表,这阻碍了对 PD 中焦虑的研究。本研究旨在评估汉密尔顿焦虑量表(HARS)、贝克焦虑量表(BAI)和医院焦虑抑郁量表(HADS)在 PD 患者中的临床特性。
342 名 PD 患者接受了标准化评估,包括对焦虑障碍的诊断和统计手册的结构化访谈,以及 HARS、BAI 和 HADS 的完成。在 60 名患者中评估了 HARS 的观察者间可靠性;在 213 名和 217 名患者中分别评估了 BAI 和 HADS 的测试-重测可靠性。
34%的患者患有焦虑障碍,而另外 11.4%的患者在没有焦虑障碍诊断的情况下出现了临床显著的焦虑症状。可接受性、分数分布和不同焦虑水平的已知组有效性是充分的。HARS 的观察者间可靠性和 BAI 和 HADS 的测试-重测可靠性良好。HARS 但不是 BAI 和 HADS 具有令人满意的项目间相关性、收敛有效性和因子结构。对于所有量表,阳性预测值较差,阴性预测值中等。
鉴于这三种评定量表的已知组有效性充分,这些量表在临床实践或研究中均可能有助于评估症状严重程度。本研究中焦虑量表的结构有效性存在局限性,这对其在 PD 中的适用性提出了质疑。